EZH2 and acute lymphoblastic leukemia: In all tested cell lines, the incubation with SAM-competitive EZH2 inhibitors but not with the SAH-hydrolase inhibitor DZNep led to a significant increase in oxaliplatin resistance which is shown representatively for the CTCL cell line HH and the T-ALL cell line Jurkat (Figure 2A) and can be found for all cell lines in Supplementary Figure S2A.